Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,455 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Richard William Scalzo also recently made the following trade(s):

• On Wednesday, September 18th, Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock. The stock was sold at an average price of $34.55, for a total value of $48,024.50.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded down $0.86 during midday trading on Wednesday, hitting $27.47. 565,801 shares of the stock traded hands, compared to its average volume of 1,450,959. Dyne Therapeutics, Inc. has a one year low of $10.33 and a one year high of $47.45. The firm has a market capitalization of $2.80 billion, a P/E ratio of -7.96 and a beta of 1.09. The firm has a 50-day moving average of $30.85 and a two-hundred day moving average of $35.36.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

DYN has been the topic of several recent research reports. Royal Bank of Canada started coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price target on the stock. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Finally, Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $50.82.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the 3rd quarter worth about $36,000. US Bancorp DE lifted its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in Dyne Therapeutics during the third quarter worth $62,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.